4-Hydrazinyl-N-methylbenzeneethanesulfonamide hydrochloride
CAS: 42381-27-1
Ref. 3D-FH23878
1g | Ausgelaufen | ||
50mg | Ausgelaufen | ||
100mg | Ausgelaufen | ||
250mg | Ausgelaufen | ||
500mg | Ausgelaufen |
Produktinformation
- 4-Hydrazino-N-methylbenzeneethanesulfonamide hydrochloridep-[b-(Methylsulfonamido)ethyl]phenylhydrazine hydrochloride
- 2-(4-hydrazinophenyl)-N-methylethanesulfonamide hydrochloride
- 4-Hydrazino-N-Methyl Benzene Ethane Sulfonamide Hydrochloride
- 4-Hydrazino-N-Methylbenzenethanesulfonamide Hydrochloride
- Benzeneethanesulfonamide, 4-hydrazino-N-methyl-, monohydrochloride
- Benzeneethanesulfonamide, 4-hydrazinyl-N-methyl-, hydrochloride (1:1)
- p-[beta-(Methylsulfonamido)ethyl]phenylhydrazine hydrochloride
- p-[β-(Methylsulfonamido)ethyl]phenylhydrazine hydrochloride
This drug is a beta-adrenergic blocking agent that has been shown to be useful in the treatment of high blood pressure. It is also used for the treatment of asthma, chronic obstructive pulmonary disease, and cardiac arrhythmias. The optical isomers are reported to have different pharmacological properties. This drug binds to beta-adrenergic receptors and prevents the binding of epinephrine (adrenaline) to these receptors, thereby inhibiting its effects on the heart and lungs. 4-Hydrazinyl-N-methylbenzeneethanesulfonamide hydrochloride is metabolized by carboxylic esters in the liver. Hydrolysis leads to release of 4'-hydroxymethylene-4H-1,2,4-triazolium cation, which produces an inhibitory effect on erythrocyte aggregation.